Trial · NCT07532525
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
NCT07532525, Phase 1, Recruiting, University of Michigan Rogel Cancer Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma. Trials, record NCT07532525. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07532525
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
- NCT number
- NCT07532525
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 12 participants, estimated
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Pomalidomide
- First posted
- 2026-04-16
- Last updated
- 2026-10-15
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of adverse events | Within first 56 days following pomalidomide initiation | Will assess the safety and tolerability of pomalidomide following CD19 chimeric antigen receptor T-cell (CD19CART) therapy for recurrent/refractory B-cell leukemia/lymphoma. Hematologic and non-hematologic toxicity within the first 56 days following the initiation of pomalidomide will be monitored. All observed toxicities, including dose-limiting toxicity will be summarized in terms of type (organ affected or laboratory determination), severity (by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0), duration, and reversibility or outcome. Tables will be created to summarize toxicities. |
| Secondary | CD19CART transgene expression | At days 0, 7, 14, 28, and 56 | Anti-CD19 (FMC63) CAR-T qPCR assay |
| Secondary | CD19CART transgene expression | At 1 year | A Spaghetti plot of individual transgene expression levels will be presented through 1-year post-pomalidomide initiation, with a population average superimposed on the plot. |
| Secondary | Overall survival | Up to 1 year | Kaplan-Meier estimates with confidence intervals will be presented and proportions will be accompanied by 95% confidence intervals. Subject to available event rates for model convergence, a Cox proportional hazards model with transgene expression as a continuous predictor will be used to explore potential association with overall survival. |
| Secondary | Event-free survival (EFS) | Up to 1 year | 1-year EFS estimates with confidence intervals will be presented and proportions will be accompanied by 95% confidence intervals. Events will be defined as disease relapse, progression, or death due to any cause. |
| Secondary | Lymphocyte profiles | At baseline and days 7, 14, 28, and 56 | Immunophenotyping of lymphocyte profiles will be plotted via a Spaghetti plot with a heat map color scheme to correlate T-cell differentiation profiles with CD19CART transgene expression at the concurrent time points. |
| Secondary | Serum cytokine and chemokine levels | At baseline and days 7, 14, 28, and 56 | Will be plotted via a Spaghetti plot with a heat map color scheme to correlate cytokine/chemokine levels with CD19CART transgene expression at the concurrent time points. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07532525
GET https://conductscience.org/api/trials/v1/NCT07532525/registered